Natera, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NTRA research report →
Companywww.natera.com
Natera, Inc. , a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
- CEO
- Steven Leonard Chapman
- IPO
- 2015
- Employees
- 4,424
- HQ
- Austin, CA, US
Price Chart
Valuation
- Market Cap
- $29.35B
- P/E
- -128.12
- P/S
- 11.73
- P/B
- 16.35
- EV/EBITDA
- -103.77
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 65.16%
- Op Margin
- -12.97%
- Net Margin
- -9.05%
- ROE
- -15.13%
- ROIC
- -11.92%
Growth & Income
- Revenue
- $2.31B · 35.90%
- Net Income
- $-208,160,000 · -9.31%
- EPS
- $-1.52 · 0.65%
- Op Income
- $-309,911,000
- FCF YoY
- 57.58%
Performance & Tape
- 52W High
- $256.36
- 52W Low
- $131.81
- 50D MA
- $200.80
- 200D MA
- $200.56
- Beta
- 1.57
- Avg Volume
- 1.41M
Get TickerSpark's AI analysis on NTRA
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 8, 26 | Sheena Jonathan | sell | 200 |
| May 8, 26 | Sheena Jonathan | sell | 900 |
| May 8, 26 | Sheena Jonathan | sell | 700 |
| May 8, 26 | Sheena Jonathan | sell | 200 |
| May 8, 26 | Sheena Jonathan | sell | 1,150 |
| May 13, 26 | Sheena Jonathan | sell | 85 |
| May 13, 26 | Sheena Jonathan | sell | 96 |
| May 13, 26 | Sheena Jonathan | sell | 345 |
| May 13, 26 | Sheena Jonathan | sell | 360 |
| May 13, 26 | Sheena Jonathan | sell | 290 |
Our NTRA Coverage
We haven't published any research on NTRA yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate NTRA Report →